NCT02729961 2019-10-10Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell LymphomaUniversity of WashingtonPhase 1/2 Withdrawn
NCT03205891 2018-01-17Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell LymphomasM.D. Anderson Cancer CenterPhase 1 Withdrawn